PMA device
Animas Vibe System
Animas Corp. · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Dec 24, 2015, newest Dec 24, 2015Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
3
Naming "Animas Vibe"
MAUDE reports
85,527
Brand "Animas Vibe", since 2015
PubMed studies
7
Mentioning "Animas Vibe"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Animas Vibe System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ANIMAS VIBE SYSTEMPMA supplement
P130007-S004 · Decided Dec 24, 2015 · 238 days after receipt · Panel Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Animas Vibe", any status and sponsor, newest update first.
Azienda Ospedaliero-Universitaria CareggiAcademic, hospital or other
NCT03557892 · 28 participants · Start Apr 1, 2018 · Primary completion Dec 20, 2019
Device: CGM+CSII; MDI with degludec · For: Diabetes Mellitus, Type 1
Sites: Florence, Italy
Medical University of GrazAcademic, hospital or other
NCT02359617 · 10 participants · Start Feb 2013 · Primary completion Oct 2014
Device: glucose sensing · For: Type 1 Diabetes
Sites: Graz, Austria
Becton, Dickinson and CompanyPublic (BDX)
NCT01557907 · 23 participants · Start Feb 2012 · Primary completion May 2012
Device: Subcutaneous delivery via Medtronic Quick-Set; Intradermal delivery via the BD Research Catheter Set · For: Diabetes
Sites: Neuss, Germany
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Animas Vibe", and for the whole product code for context.
This brand
85,527 reports: 83,781 malfunction, 1,526 injury, 12 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
- ANIMAS VIBEMalfunction
2531779-2020-00249 · Received Sep 14, 2020
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Electrical /Electronic Property Problem
Patient problem as coded: No Consequences Or Impact To Patient
- ANIMAS VIBEMalfunction
2531779-2020-00250 · Received Sep 14, 2020
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Failure to Read Input Signal
Patient problem as coded: No Consequences Or Impact To Patient
- ANIMAS VIBEMalfunction
2531779-2020-00252 · Received Sep 14, 2020
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Device Displays Incorrect Message; Fail-Safe Problem
Patient problem as coded: No Consequences Or Impact To Patient
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1034-2015 · Started Sep 6, 2011 · Posted by FDA Jan 30, 2015
Reason given: Calibration factors in the pump overwritten during a programming step. The force sensor could send a lower signal value to the pump processor, with loss of prime warnings, occlusion alarms and the pump unable to detect a cartridge during the prime sequence. Field action initiated 8/29/2011.
Cause as FDA categorized it: Software design (manufacturing process) · Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Published research
The most relevant PubMed records for "Animas Vibe"[tiab]. The summary above synthesizes these.
- Patient Controlled, Off-label Use of Continuous Glucose Monitoring: Real-World Medical Costs and Effects of Patient Controlled Sensor Augmented Pump Therapy in Adult Patients Type 1 Diabetes.
Hidefjäll P, Berg L · J Diabetes Sci Technol · 2021Research Support, Non-U.S. Gov't
- Comparing Insulin Pump Devices in Real Life: The AWeSoMe Study Group Prospective Experience.
Rachmiel M, Levy-Shraga Y, Gruber N, et al. · Diabetes Technol Ther · 2019Observational Study
- Insulin pump failures in Italian children with Type 1 diabetes: retrospective 1-year cohort study.
Rabbone I, Minuto N, Bonfanti R, et al. · Diabet Med · 2017
- High reported treatment satisfaction in people with type 1 diabetes switching to latest generation insulin pump regardless of previous therapy.
Barnard KD, Bromba M, de Lange M, et al. · J Diabetes Sci Technol · 2015Multicenter Study, Research Support, Non-U.S. Gov't
- Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies.
Borot S, Franc S, Cristante J, et al. · J Diabetes Sci Technol · 2014Clinical Trial, Comparative Study
- The Insulin Treatment Satisfaction Questionnaire and Assessment of Satisfaction with a Latest-generation Insulin Pump.
Bromba M, Campbell F, Levy BL · Eur Endocrinol · 2015
- Electromagnetic interference from electronic devices used in the management of type 1 diabetes can impair the performance of an avalanche transceiver in search mode.
Miller SC · Wilderness Environ Med · 2015
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.